← Arbutus Biopharma Corp
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $23.4m | $54.3m | $36.9m | $31.8m | $52.3m | $109.3m | $30.8m | $26.3m | $36.3m | $18.0m | |
| Prepaid Expense and Other Assets, Current | $1.3m | $2.1m | $2.8m | $1.8m | $3.1m | $4.4m | $2.9m | $4.2m | $2.3m | $1.5m | |
| Cash, Cash Equivalents, and Short-term Investments | $130.6m | $126.4m | $124.6m | — | $123.3m | $191.0m | $184.3m | $132.3m | $122.6m | $91.5m | |
| Short-term Investments | $107.1m | $72.1m | $87.7m | $59.0m | $71.0m | $46.0m | $116.1m | $99.7m | $86.3m | $73.5m | |
| Assets, Current | $132.6m | $129.4m | $129.2m | $93.8m | $127.7m | $160.7m | $151.1m | $132.0m | $127.3m | $94.5m | |
| Property, Plant and Equipment, Net | $6.9m | $12.2m | $10.1m | $8.7m | $6.9m | $6.0m | $5.1m | $4.7m | $3.3m | $32k | |
| Goodwill | $24.4m | $24.4m | $22.5m | $0 | — | — | — | — | — | — | |
| Intangible Assets, Net (Excluding Goodwill) | $99.4m | $58.6m | $43.8m | $0 | — | — | — | — | — | — | |
| Operating Lease, Right-of-Use Asset | — | — | — | $2.7m | $2.4m | $2.1m | $1.7m | $1.4m | $1.0m | $0 | |
| Other Assets, Noncurrent | — | — | — | $293k | $44k | $61k | $103k | $0 | $34k | $130k | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $273k | $402k | $1.4m | $1.2m | $1.3m | $899k | $1.4m | $1.8m | $2.4m | $1.4m | |
| Assets | $275.9m | $237.2m | $227.9m | $105.5m | $137.1m | $204.5m | $195.4m | $144.4m | $131.7m | $94.6m | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $340k | $390k | $383k | $372k | $425k | $483k | $547k | |
| Operating Lease, Liability, Noncurrent | — | — | — | $3.0m | $2.6m | $2.2m | $1.8m | $1.3m | $806k | $199k | |
| Deferred Revenue, Current | $15k | $2.7m | — | — | — | — | $16.5m | $11.8m | $7.6m | $0 | |
| Deferred Revenue, Noncurrent | $0 | $0 | — | — | — | — | $6.0m | $0 | $2.9m | $0 | |
| Liabilities, Current | $10.6m | $14.6m | $11.2m | $7.8m | $9.5m | $11.2m | $32.9m | $22.5m | $15.6m | $6.0m | |
| Deferred Income Tax Liabilities, Net | — | — | $12.7m | $0 | — | — | — | — | — | — | |
| Long-term Debt | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | |
| Deferred Tax Liabilities, Net | $41.3m | $16.9m | $12.7m | $0 | — | — | — | — | — | — | |
| Liabilities | $72.9m | $54.7m | $27.7m | $32.8m | $35.1m | $35.0m | $58.6m | $38.4m | $34.3m | $18.0m | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | $48.9m | — | — | — | — | — | — | — | — | |
| Common Stock, Value, Issued | $867.4m | $876.1m | $879.4m | $898.5m | $985.9m | $1.3b | $1.3b | $1.3b | $1.4b | $1.4b | |
| Additional Paid in Capital | $36.5m | $42.8m | $48.1m | $55.2m | $60.8m | $65.5m | $72.4m | $81.3m | $82.0m | $83.3m | |
| Retained Earnings (Accumulated Deficit) | ($651.1m) | ($738.1m) | ($805.2m) | ($970.1m) | ($1.0b) | ($1.1b) | ($1.2b) | ($1.3b) | ($1.3b) | ($1.4b) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($49.8m) | ($48.2m) | ($48.2m) | ($48.2m) | ($48.2m) | ($48.3m) | ($50.5m) | ($48.4m) | ($48.1m) | ($48.1m) | |
| Stockholders' Equity Attributable to Parent | $203.0m | $182.5m | $200.2m | $72.7m | $102.0m | $169.4m | $136.9m | $106.0m | $97.4m | $76.6m | |
| Liabilities and Equity | $275.9m | $237.2m | $227.9m | $105.5m | $137.1m | $204.5m | $195.4m | $144.4m | $131.7m | $94.6m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.